MTEM Insider Trading

Insider Ownership Percentage: 13.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $844,681.20

Molecular Templates Insider Trading History Chart

This chart shows the insider buying and selling history at Molecular Templates by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Molecular Templates Share Price & Price History

Current Price: $0.00
Price Change: Price Decrease of -0.0001 (-50.00%)
As of 04/3/2025 10:30 AM ET

This chart shows the closing price history over time for MTEM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.00Closing price on 04/03/25:

Molecular Templates Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Molecular Templates (NASDAQ:MTEM)

95.47% of Molecular Templates stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MTEM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100$0$100Total InflowsTotal Outflows
Molecular Templates logo
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Read More on Molecular Templates

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

52 Week Range

Now: $0.00
Low: $0.00
High: $2.04

Volume

520 shs

Average Volume

4,039,411 shs

Market Capitalization

$658.40

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Who are the company insiders with the largest holdings of Molecular Templates?

Molecular Templates' top insider shareholders include:
  1. Target N V Biotech (Major Shareholder)
  2. Target N V Biotech (Major Shareholder)
Learn More about top insider investors at Molecular Templates.